The dengue vaccine is effective in preventing any of the four serotypes of the virus
Takeda Pharmaceutical Company Limited today announced that Phase 3 testing of its dengue vaccine meets the primary efficacy endpoint.
This first analysis of tetravalent immunization against dengue activity studies (TIDES) showed that the attenuated tetravalent in vivo dengue vaccine (TAK-003) vaccine vaccine was effective in preventing dengue fever caused by one of four virus serotypes. While the review of the extensive data set continues, TAK-003 has been well tolerated and significant safety issues have not yet occurred.
The candidate for tetanus tetanus vaccine (TAK-003) from Takeda is based on a type virus serotype 2 live attenuated dengue, which provides the genetic "skeleton" for four vaccine viruses.
The TIDES Trial continues and other results are expected later this year, along with the results of the next phases of the 3rd study.
"We are very excited about the performance of our dengue vaccine in a study that takes us a step closer to helping the world cope with the enormous burden of dengue," said MUDr. Rajeev Venkayya, President of the Marketing Department of Vaccination. Global in Takeda. "We are very excited to publish the data as quickly as possible in the peer-reviewed journal, and in parallel, we are making progress in clinical development, commercial production and stakeholder consultation to support the possible future release of a global vaccine"
The TIDES study, Takeda's largest interventional clinical trial, included over 20,000 healthy children and adolescents aged four to 16 years living in dengue endemic areas. The study was designed to evaluate the efficacy, safety and immunogenicity of two doses of TAK-003 in individuals exposed to dengue and in individuals without previous treatment.
TAK-003 is currently not licensed anywhere in the world.